BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways-Reference-Cited by-同舟云学术

BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways

Published:2016-03-21 Issue:39 Volume:35 Page:5179-5190
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Jubierre L,Soriano A,Planells-Ferrer L,París-Coderch L,Tenbaum S P,Romero O A,Moubarak R S,Almazán-Moga A,Molist C,Roma J,Navarro S,Noguera R,Sánchez-Céspedes M,Comella J X,Palmer H G,Sánchez de Toledo J,Gallego S,Segura M F

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc201650.pdf

Reference55 articles.

1. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363: 1324–1334.

2. Irwin MS, Park JR . Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am 2015; 62: 225–256.

3. Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR et al. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol 2014; 89: 889–895.

4. Popovic R, Licht JD . Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov 2012; 2: 405–413.

5. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904–917.

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting SWI/SNF ATPases reduces neuroblastoma cell plasticity;The EMBO Journal;2024-08-22

2. Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer;Cancer Cell;2024-08

3. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer;Proceedings of the National Academy of Sciences;2024-04

4. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer;2024-03-03

5. Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer;2024-01-24